Xilio Therapeutics, Inc. (XLO)
| Market Cap | 58.43M +61.0% |
| Revenue (ttm) | 64.09M +327.3% |
| Net Income | -21.83M |
| EPS | -3.32 |
| Shares Out | 6.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,143 |
| Open | 8.57 |
| Previous Close | 8.95 |
| Day's Range | 8.57 - 9.25 |
| 52-Week Range | 6.47 - 12.74 |
| Beta | -0.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About XLO
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in... [Read more]
Financial Performance
In 2025, Xilio Therapeutics's revenue was $43.77 million, an increase of 589.88% compared to the previous year's $6.34 million. Losses were -$35.04 million, -39.84% less than in 2024.
Financial StatementsNews
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell ...
Xilio Therapeutics Earnings release: Q2 2026
Xilio Therapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Xilio Therapeutics Quarterly report: Q2 2026
Xilio Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people ...
Xilio Therapeutics appoints Ben Harshbarger as chief legal officer
Xilio Therapeutics (XLO) announced the appointment of Ben Harshbarger as chief legal officer. recently, he served as chief legal officer at Astria Therapeutics, Inc. until its acquisition. Published f...
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people ...
Xilio Therapeutics Registration statement: Registration filing
Xilio Therapeutics filed a registration statement on May 27, 2026, providing details about a securities offering with the SEC.
Xilio Therapeutics files $250M mixed securities shelf
07:50 EDT Xilio Therapeutics (XLO) files $250M mixed securities shelf
Xilio Therapeutics Registration statement: Registration filing
Xilio Therapeutics filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2
Xilio Therapeutics Earnings release: Q1 2026
Xilio Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Xilio Therapeutics Quarterly report: Q1 2026
Xilio Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Xilio Therapeutics Proxy statement: Proxy filing
Xilio Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Xilio announces new preclinical data for XTX601 at AACR
Xilio Therapeutics (XLO) announced new preclinical data for XTX601, a masked T cell engager targeting claudin 18.2, at the American Association for Cancer Research Annual Meeting, taking place from Ap...
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models
Xilio Therapeutics appoints Blanchard to its Board of Directors
Xilio Therapeutics (XLO) announced the appointment of Cheryl Blanchard, Ph.D. to the company’s board of directors. The company also announced that Christina Rossi has stepped down from its board of…
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people...
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026
Xilio Therapeutics Annual report: Q4 2025
Xilio Therapeutics has published its Q4 2025 annual report on March 23, 2026.
Xilio Therapeutics Earnings release: Q4 2025
Xilio Therapeutics released its Q4 2025 earnings on March 23, 2026, summarizing the period's financial results.
Xilio Therapeutics Annual report: Q4 2025
Xilio Therapeutics has published its Q4 2025 annual report on March 23, 2026.
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people...
Xilio Therapeutics Inc trading halted, news pending
19:50 EDT Xilio Therapeutics (XLO) Inc trading halted, news pending
Xilio Therapeutics announces 1-for-14 reverse stock split
Xilio Therapeutics (XLO) announced that it will implement a 1-for-14 reverse stock split of the issued shares of the company’s common stock, effective on March 13, 2026. Published first on…
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people...